English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aspirin might contribute to public health policy by reducing the risk of vascular events and colorectal cancer. These are significant causes of disease, disability and death in the population and increased aspirin use in the population might be beneficial. In this article, a summary of the contemporary literature is presented and policy developments are suggested.The benefit of aspirin in the secondary prevention of vascular events is well accepted and the use of the medicine for this indication is an established part of mainstream clinical practice, unless individual patients have specific contraindications. It is of concern, therefore, that there appears to be an under use of aspirin prophylaxis for the indication of secondary prevention, particularly myocardial infarction.1 Given that aspirin is easily available and inexpensive, factors underpinning the under use of the medicine need to be identified, in order to develop targeted policies to address this matter.This remains a controversial topic and the evidence base has been subject to different interpretations by different authorities.2 Further trials are …

On the unfulfilled public health potential of aspirin